实体肿瘤患者行冠状动脉旁路移植术的早期与长期结果
本研究回顾2005至2016年单中心4079例孤立CABG患者,其中82例合并实体肿瘤(占2.5%活跃恶性肿瘤中的一部分)。肿瘤患者30天死亡率显著高于非肿瘤患者(4.9% vs 1.8%),但癌症并非院内死亡的独立危险因素。中位随访58±12个月,总体5年生存率60%,肺癌亚组仅32%。
要点
- 合并实体肿瘤不应成为拒绝CABG的理由,其冠脉病变解决后80%患者可安全接受肿瘤手术。
- 肿瘤患者术后肺部并发症风险独立升高,但院内死亡风险经校正后无显著增加。
- 肺癌患者5年生存率仅32%,显著低于其他实体肿瘤亚组。
核心结论
- 基于本研究结果,不应以预后更差或移植物耐久性更低为由拒绝为实体器官肿瘤患者施行CABG。
- 需要更大样本量的进一步研究予以验证。
研究设计与样本
- 单中心回顾性队列研究,2005至2016年共4079例孤立CABG患者,其中82例合并实体器官肿瘤(平均年龄71±7岁)。
- 肿瘤亚组分为肺(9例,11%)、胃肠(16例,20%)、泌尿(48例,58%)及其他实体肿瘤(9例,11%)。
- 通过临床数据库与国家医院信息系统确定性记录链接识别长期生存率和无主要不良心血管事件率。
主要发现
- 最常见的肿瘤为前列腺癌、结肠癌和肺癌。
- 肿瘤患者较非肿瘤患者年龄显著更大且合并症比例更高,但各肿瘤亚组间无显著差异。
- 肿瘤患者30天死亡率显著高于非肿瘤患者(4.9% vs 1.8%)。
- 逻辑回归分析显示,癌症是术后肺功能障碍的独立危险因素,但不是院内死亡的独立危险因素。
- 中位随访58±12个月,总体5年生存率60%(95%CI 47-71%),肺癌亚组仅32%(95%CI 5-65%)。
关键数值与推荐
- 肿瘤患者30天死亡率为4.9%,非肿瘤患者为1.8%。
- 总体5年生存率60%(95%CI 47-71%);肺癌亚组5年生存率32%(95%CI 5-65%)。
- 5年无主要不良心血管事件率为64%(95%CI 52-74%),各亚组间无显著差异,与非肿瘤人群相当。
- 80%的患者在解决冠心病后安全接受了肿瘤外科切除术。
临床怎么用
- 对合并实体肿瘤的冠心病患者,不应仅因肿瘤诊断而拒绝CABG。
- 术前应充分评估并防范术后肺功能障碍,尤其对肿瘤患者。
- CABG后可安全实施肿瘤外科切除的比例达80%,支持多学科协作决策。
局限性
- 单中心回顾性研究,样本量有限(82例肿瘤患者)。
- 各肿瘤亚组样本量小(如肺癌仅9例),亚组分析效力不足。
- 需要更大样本量的进一步研究验证结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our goal was to analyse a consecutive series of patients with solid organ tumours undergoing coronary artery bypass grafting (CABG) by defining the risk factors for early and long-term outcomes. METHODS: Between 2005 and 2016, a consecutive series of 4079 patients underwent isolated CABG at our institution. Of 103 patients (2.5%) with active malignancy, we enrolled 82 patients (mean age 71 ± 7 years) with solid organ tumours, divided into 4 subgroups: lung (9 patients-11%), gastroenteric (16 patients-20%), urinary (48 patients-58%) and other solid tumours (9 patients-11%). A deterministic record linkage between the clinical database and the National Hospital Information System allowed identification of long-term survival rates and freedom from major adverse cardiovascular events (acute myocardial infarction, repeated admissions for percutaneous coronary intervention and heart failure). RESULTS: The most common forms of cancer were prostate, colon and carcinoma of the lung. Compared to patients without cancer, patients with neoplasms were significantly older and had a higher rate of comorbidities, without significant differences among the cancer subgroups. The 30-day mortality rate was significantly higher in patients with cancer compared to those without cancer (4.9% vs 1.8%). However, on logistic regression analysis, cancer was an independent risk factor for postoperative pulmonary dysfunction but not for in-hospital death. The median follow-up time was 58 ± 12 months. The overall 5-year survival rate was 60% [95% confidence interval (CI) 47-71%], with a dismal 32% (95% CI 5-65%) survival rate among patients who had lung tumours only. The 5-year freedom from major adverse cardiovascular events was 64% (95% CI 52-74%), without significant differences among subgroups, and was comparable to that of the non-cancer population. Resolution of coronary heart disease allowed safe cancer surgical resection in 80% of the population. CONCLUSIONS: Based on the results from the present study, CABG should not be denied to patients with solid organ tumours by claiming a worse prognosis or less graft durability. Further studies with larger numbers are warranted.
引用
- Garatti A, D'Ovidio M, Saitto G, et al. Coronary artery bypass grafting in patients with concomitant solid tumours: early and long-term results. Eur J Cardiothorac Surg. 2020. PMID: 32474575. doi:10.1093/ejcts/ezaa114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。